Hormonal
Semaglutide, administered via weekly subcutaneous injection, produces significant weight loss (mean 14.9% reduction) and improves insulin resistance, hypertension, and glycemia in adults with obesity (BMI ≥30 kg/m²).
Semaglutide is a weekly injection that helps you lose about 15% of your body weight and improves blood pressure and blood sugar. It works best when combined with a healthy diet and exercise. Common side effects like nausea are usually temporary. It is prescribed for people with a BMI of 30 or higher, or 27 or higher with health issues.
Em Wilding et al. (2021) um Ensaio Clínico Randomizado (ECR), duplo cego, controlado com placebo, em 1961 adultos, com IMC acima de 30 kg/m², durante 68 semanas, foi demonstrado que os participantes em uso do medicamento apresentaram uma perda de peso média de 14,9% (-15,3 kg) do peso corporal inicial, em comparação com uma perda de 2,4% (-2,6 kg) observada no grupo placebo. Outros efeitos encontrados com o uso da semaglutida foram a melhora da resistência à insulina, redução da pressão arterial, e dos níveis de glicemia (Zhong et al., 2022).
Why this rating
Based on a large, double-blind, placebo-controlled randomized clinical trial (Wilding et al., 2021).
Source
TERAPIAS FARMACOLÓGICAS PARA TRATAR OBESIDADE: ANÁLISE DE EFEITO E EFICÁCIA
Túlio Martins Freitas et al. · Revista Foco · 2024
DOI 10.54751/revistafoco.v17n10-082
More from this paper
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significant weight loss (up to -9.5 kg with 15 mg dose) in patients with type 2 diabetes over 40 weeks.Strong
- Orlistat, taken at 120 mg three times daily, reduces body weight by 8% over 12 months compared to 5% with placebo, and significantly reduces cardiovascular risk factors like hypertension and LDL cholesterol.Good
- Sibutramine, an appetite suppressant acting on the hypothalamus, is more effective than placebo for weight loss when combined with lifestyle changes, with 22-38% of patients achieving >5% weight loss in 3 months.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →